Literature DB >> 26978866

NOVELTIES IN MEDICAL TREATMENT OF GLAUCOMA.

Stefan Cornel, Timaru Cristina Mihaela, Iliescu Daniela Adriana, Batras Mehdi, De Simone Algerino.   

Abstract

The purpose of this study is to review the current medical treatment and the new and better alternatives for patients with glaucoma. Glaucoma refers to a group of related eye disorders that have in common an optic neuropathy associated with visual function loss. It is one of the leading causes of irreversible blindness worldwide. Glaucoma can damage vision gradually so it may not be noticed until the disease is at an advanced stage. Early diagnosis and treatment can minimize or prevent optic nerve damage and limit glaucoma-related vision loss. Nowadays, research continues for the improvement of current medical treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26978866      PMCID: PMC5712934     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  36 in total

1.  Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.

Authors:  Richard A Lewis; Gregory J Katz; Mark J Weiss; Theresa A Landry; Jaime E Dickerson; John E James; Steven Y Hua; E Kenneth Sullivan; Dawnelle B Montgomery; David T Wells; Michael V W Bergamini
Journal:  J Glaucoma       Date:  2007-01       Impact factor: 2.503

2.  Nanoparticles in the ocular drug delivery.

Authors:  Hong-Yan Zhou; Ji-Long Hao; Shuang Wang; Yu Zheng; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

Review 3.  Anti-VEGF therapy for glaucoma.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Curr Opin Ophthalmol       Date:  2010-03       Impact factor: 3.761

4.  Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration.

Authors:  Hu Yang; Puneet Tyagi; Rajendra S Kadam; Christopher A Holden; Uday B Kompella
Journal:  ACS Nano       Date:  2012-08-21       Impact factor: 15.881

5.  Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops.

Authors:  Tina T Wong; Gary D Novack; Jayaganesh V Natarajan; Ching Lin Ho; Hla M Htoon; Subbu S Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

Review 6.  Gene therapy for glaucoma.

Authors:  Anna-Maria Demetriades
Journal:  Curr Opin Ophthalmol       Date:  2011-03       Impact factor: 3.761

7.  Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.

Authors:  Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Hideki Suganami; Makoto Araie
Journal:  JAMA Ophthalmol       Date:  2015-07       Impact factor: 7.389

8.  Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

Authors:  Hussein O Ammar; H A Salama; M Ghorab; A A Mahmoud
Journal:  AAPS PharmSciTech       Date:  2009-06-18       Impact factor: 3.246

9.  Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients.

Authors:  Nicola Pescosolido; Vittorio Gatto; Alessio Stefanucci; Dario Rusciano
Journal:  Ophthalmic Physiol Opt       Date:  2015-01-20       Impact factor: 3.117

10.  Controversy: Is Benzalkonium Chloride Necessary in Antiglaucoma Drops?

Authors:  Y Louati; T Shaarawy
Journal:  J Curr Glaucoma Pract       Date:  2012-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.